Back to Companypage
Business Logo
 
  • Konzern
    • About us
    • Management
    • Press
    • Events
    • Employees
    • Careers
    • Sponsoring
  • Business Units
    • Analytical Instrumentation
    • Life Science
    • Optics
  • Produkte
    • Products from A to Z
  • Investor | Media Relations
    • Key Figures
    • Share
    • Financial Reports
    • Annual Document
    • Corporate Governance
    • Ad Hoc Announcements
    • Director’s Dealings
    • Annual General Meeting
    • Financial Calendar
    • Press Releases
Investor | Media Relations
  • Key Figures
  • Share
  • Financial Reports
  • Annual Document
  • Corporate Governance
  • Corporate Governance Declaration
  • Ad Hoc Announcements
    • Ad Hoc Archive
  • Director’s Dealings
  • Annual General Meeting
  • Financial Calendar
  • Press Center

Analytik Jena Company

  • AJ Blomesystem GmbH
  • AJ Cybertron GmbH
  • AJ Innuscreen GmbH
  • AJ Roboscreen GmbH
  • AJZ Engineering GmbH
  • Biometra GmbH
  • CyBio AG
  • Analytik Jena Worldwide |
  • Languages
    • English
    • Deutsch
 

zurück zur Übersicht

Analytik Jena at record level, even after the first half of 2007/2008
  • Group sales increase by 22.5 %
  • Operating earnings increased by 37.8 %
  • Increase in liquidity of EUR 5 m through a new borrower's note loan
  • Disposal of project business completed

Jena, May 15, 2008 — Analytik Jena (Frankfurt DE0005213508, Prime Standard: AJA) has reported its 2007/2008 half year results. The company continued its positive business performance in the second quarter. Consolidated sales increased by 22.5 % to EUR 41.7 m (previous year: EUR 34.0 m). This performance is even more clearly reflected on a half year basis in the operating earnings, which grew by 37.8 % to almost EUR 2.9 m (previous year: EUR 2.1 m). "The sales and earnings performance in the first six months of 2007/2008 make us feel very optimistic for the second half year", explained Klaus Berka, Chairman of the Executive Board of Analytik Jena AG. "We grew in all divisions in the instrument business. For the first time ever, the analytical solutions business unit achieved half year sales of over EUR 20.0 m. This is a sign that our high-tech products are penetrating the market to a higher and higher degree, particularly in light of a US dollar which is still much weaker. With the fulfilment of all necessary requirements per May 9, 2008, the sale of the project business is finalized. It will be a very important step focussing on the growth segments of the instrument business.

We expect that the positive business performance will continue in the quarters to come." All in all, the Group increased sales in the instrument division by 24.8 % to EUR 27.114 m (previous year: EUR 21.722 m) in the first half of the financial year. At EUR 31.573 m (previous year: EUR 25.776 m), the export rate comes to 75.8 %. With a 22.9 % increase to EUR 20.575 m (previous year: EUR 16.748 m), the analytical solutions unit continues to make the largest contribution to sales in the instrument business. The bio solutions business unit increased its sales by 35.5 %. Income of EUR 2.048 m (previous year: EUR 1.512 m) was achieved with the reagents and instruments. In the optical solutions unit, sales increased by 29.7 % from EUR 3.462 m to EUR 4.491 m in the first half year. In the discontinued project solutions business unit, revenue of EUR 14.557 m (previous year: EUR 12.282 m) was achieved. As at March 31, 2008, gross profit increased by 15.1 % from EUR 13.797 m to EUR 15.883 m. The overall gross margin comes to 38.1 % (previous year: 40.6 %) and is below the comparable value. This is due to the ongoing weakening of the dollar and general price pressure on the products from the Jena-based Group. Consequently, results remained approximately the same in a direct comparison of quarters - despite the increase in sales. On the basis of the half year, a new record mark was achieved with a 37.8 % increase in operating earnings from EUR 2.075 m to EUR 2.860 m. Taking the fact that the instrument business will be continued on its own in the future, Analytik Jena actually achieved operating earnings of EUR 2.952 m (previous year: EUR 2.271 m), which represents a 10.9 % EBIT margin. The balance from financial income and expenses increased in the reporting period mainly due to currency losses of EUR 0.241 m to EUR 0.959 m. The US dollar fell by more than 10 cents within a single quarter and this had a discernibly negative impact.

Nevertheless, earnings before tax increased to EUR 1.901 m (previous year: EUR 1.834 m). If the focus is placed exclusively on the instrument business which will be continued in the future, Analytik Jena can actually record earnings before tax of EUR 2.340 m. All in all, the group achieved net profit for the period of EUR 1.411 m (previous year: EUR 1.135 m) in the first half of 2007/2008. This represents a 24.3 % increase in earnings. Earnings per share (basic) currently come to EUR 0.28 (previous year: EUR 0.24). As at the end of the period under review, the Group's cash and cash equivalents come to EUR 6.717 m (September 30, 2007: EUR 6.990 m). Through a new borrower's note loan which was issued by Hypovereinsbank in the middle of May, cash and cash equivalents will increase by EUR 5.0 m. At the end of the period under review, the Group's total assets had increased to EUR 68.044 m (September 30, 2007: EUR 63.141 m). This represents an equity ratio of 46.5 %. If one looks at the instrument area, which will be continued on its own in the future, the equity ratio is as high as 60.8 %. Analytik Jena confirms the forecast which has already been disclosed for the instrument business. This forecast predicts revenue over EUR 51.0 m with operating earnings of EUR 4.7 m to EUR 5.2 m.

Contact:
Dr. Mario Voigt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Tel.: +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com

 
AJ Blomesystem GmbH | AJ Cybertron GmbH | AJ Innuscreen GmbH
AJ Roboscreen GmbH | AJZ Engineering GmbH | Biometra GmbH | CyBio AG
Analytik Jena AG | Contact | Imprint | Conditions of Use | Privacy Policy | Sitemap